Form 4: Astria Therapeutics' Chief Medical Officer Exercises Options and Sells Shares

Christopher Morabito, Chief Medical Officer of Astria Therapeutics, exercised stock options and sold 10,000 shares of common stock on April 1, 2024, under a pre-arranged trading plan.

Summary

• On April 1, 2024, Christopher Morabito, the Chief Medical Officer of Astria Therapeutics, exercised stock options to purchase 10,000 shares of common stock at a price of $3.87 per share.
• Simultaneously, Morabito sold 10,000 shares of Astria Therapeutics' common stock at a weighted average price of $13.5939 per share, with individual sales ranging from $13.37 to $13.76.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on March 31, 2023.
• Following the reported transactions, Morabito directly owns 80,000 stock options.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing insider transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about stock option exercises and sales.

Industry Context

Form 4 filings are a routine part of the regulatory landscape, providing transparency into the transactions of company insiders. The use of a 10b5-1 plan suggests the insider's transactions were pre-planned and not based on any material non-public information.

Stakeholder Impact

• The sale of shares by a high-ranking officer could be perceived negatively by some investors, although the existence of a pre-arranged trading plan mitigates this concern.

Key Dates